title: [Standardization of evaluation for target molecule in cancer therapy].
abstract: The individualized-therapy for the gastrointestinal tract cancer is started by the emergence of molecular targeted-therapy. The patients' selection for treatment is now performed by evaluating the expression level of the targeted molecules and/or the gene mutation analysis using the pathological specimens. Pathologists should make diagnosis and select patients for the fittest molecular targeted therapy in colon cancer, stomach cancer and gastrointestinal stromal tumor(GIST). In the present paper, we focused and discussed the points of the evaluation of the targeted-molecule in pathological materials for selecting patients using the examples of HER2 test in gastric cancer and K-RAS muation in colon cancer.
authors.affiliation: Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ochiai
mesh_terms: D046152:Gastrointestinal Stromal Tumors / Q000235:genetics* / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D058990:Molecular Targeted Therapy / Q000592:standards*; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D018631:ras Proteins / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D018631:ras Proteins; C117307:KRAS protein, human; C508053:ERBB2 protein, human